Tsiara E, Makri S, Skaperda Z, Giannakoulas N, Vasilopoulos G, Kouretas D
Biomed Rep. 2025; 22(3):45.
PMID: 39882334
PMC: 11775644.
DOI: 10.3892/br.2025.1923.
Cheffai A, Boufrikha W, Rakez R, Ben Ghechir A, Laatiri M
Leuk Res Rep. 2024; 22:100487.
PMID: 39628604
PMC: 11612820.
DOI: 10.1016/j.lrr.2024.100487.
Fahim S, Tice J, Luu L, Carlson J, Richardson M, Herce-Hagiwara B
J Manag Care Spec Pharm. 2024; 30(12):1479-1485.
PMID: 39612256
PMC: 11607211.
DOI: 10.18553/jmcp.2024.30.12.1479.
Sutandyo N, Kosasih A, Sari R, Setiawan L, Rinaldi I, Maskito V
F1000Res. 2024; 13:167.
PMID: 39600341
PMC: 11589415.
DOI: 10.12688/f1000research.143170.1.
Hikmat W, Sievers A, Hausmann M, Hildenbrand G
Genes (Basel). 2024; 15(10).
PMID: 39457371
PMC: 11506876.
DOI: 10.3390/genes15101247.
[Clinical significance of IL-18 and IL-18-binding protein in bone marrow of patients with myelodysplastic syndrome].
Wang T, Ran N, Chen Q, Liu D, Zang M, Li N
Zhonghua Xue Ye Xue Za Zhi. 2024; 45(3):284-289.
PMID: 38716601
PMC: 11078664.
DOI: 10.3760/cma.j.cn121090-20231009-00178.
Long-term hematologic response after azacitidine treatment in a lower-risk myelodysplastic syndrome patient: A case report.
Loukidis K, Tschopp M
Leuk Res Rep. 2024; 21:100412.
PMID: 38292515
PMC: 10825634.
DOI: 10.1016/j.lrr.2024.100412.
Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia.
Olkinuora A, Nieminen T, Douglas S, Kauppinen A, Kontro M, Vaananen J
Leukemia. 2023; 37(11):2301-2305.
PMID: 37696923
PMC: 10624609.
DOI: 10.1038/s41375-023-02021-9.
Optimizing diagnostic methods and stem cell transplantation outcomes in pediatric bone marrow failure: a 50-year single center experience.
Vissers L, van der Burg M, Lankester A, Smiers F, Mohseny A
Eur J Pediatr. 2023; 182(9):4195-4203.
PMID: 37439851
PMC: 10570154.
DOI: 10.1007/s00431-023-05093-y.
30th Annual GPA Medicinal Chemistry Conference.
OBoyle N, Helesbeux J, Meegan M, Sasse A, OShaughnessy E, Qaisar A
Pharmaceuticals (Basel). 2023; 16(3).
PMID: 36986531
PMC: 10056312.
DOI: 10.3390/ph16030432.
Utilizing digital pathology and immunohistochemistry of p53 as an adjunct to molecular testing in myeloid disorders.
Rogers K, Abukhiran I, Syrbu S, Tomasson M, Bates M, Dhakal P
Acad Pathol. 2023; 10(1):100064.
PMID: 36970330
PMC: 10031312.
DOI: 10.1016/j.acpath.2022.100064.
Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation.
Boy M, Bisio V, Zhao L, Guidez F, Schell B, Lereclus E
Nat Commun. 2023; 14(1):588.
PMID: 36737440
PMC: 9898569.
DOI: 10.1038/s41467-023-36193-w.
Approach to Pancytopenia in a Deployed Service Member.
Gibson S, Swanson B, Tischbein C, Bathon K, Shou K, Zeman K
Fed Pract. 2022; 39(7):320-323a.
PMID: 36425352
PMC: 9648580.
DOI: 10.12788/fp.0320.
Myelodysplastic Syndrome in a Patient With Common Variable Immunodeficiency: A Rare Occurrence.
Mateti N, Vaddepally R, Skaria P, Chandra A
Cureus. 2022; 14(9):e28690.
PMID: 36199647
PMC: 9526999.
DOI: 10.7759/cureus.28690.
ABAT gene expression associated with the sensitivity of hypomethylating agents in myelodysplastic syndrome through CXCR4/mTOR signaling.
Zhao G, Li S, Wang Q, Wu W, Fu X, Zhu C
Cell Death Discov. 2022; 8(1):398.
PMID: 36163180
PMC: 9512903.
DOI: 10.1038/s41420-022-01170-7.
Cytogenetic characteristics in Vietnamese patients diagnosed with primary myelodysplastic syndromes.
Vu M, Ha H, Nguyen C
Leuk Res Rep. 2022; 18:100343.
PMID: 36032421
PMC: 9411652.
DOI: 10.1016/j.lrr.2022.100343.
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis.
Ferrada M, Savic S, Ospina Cardona D, Collins J, Alessi H, Gutierrez-Rodrigues F
Blood. 2022; 140(13):1496-1506.
PMID: 35793467
PMC: 9523373.
DOI: 10.1182/blood.2022016985.
Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
Sutandyo N, Mulyasari R, Kosasih A, Rinaldi I, Louisa M, Kevinsyah A
Asian Pac J Cancer Prev. 2022; 23(4):1107-1116.
PMID: 35485665
PMC: 9375606.
DOI: 10.31557/APJCP.2022.23.4.1107.
Azacitidine Omega-3 Self-Assemblies: Synthesis, Characterization, and Potent Applications for Myelodysplastic Syndromes.
Baroud M, Lepeltier E, El-Makhour Y, Lautram N, Bejaud J, Thepot S
Pharmaceuticals (Basel). 2021; 14(12).
PMID: 34959720
PMC: 8706301.
DOI: 10.3390/ph14121317.
Myelodysplastic Syndromes and Modalities of Treatment: An Updated Literature Review.
Zamora D, Patel G, Grossmann I, Rodriguez K, Soni M, Joshi P
Cureus. 2021; 13(12):e20116.
PMID: 34873563
PMC: 8639322.
DOI: 10.7759/cureus.20116.